Open AccessThe Effects of MDCO-2010, a Serine Protease Inhibitor, on Activated Clotting Time in Blood Obtained from Volunteers and Cardiac Surgical Patients
Author(s) -
Heezoo Kim,
Fania Szlam,
Kenichi A. Tanaka,
Andreas van de Locht,
Satoshi Ogawa,
Jerrold H. Levy
Publication year - 2012
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0b013e3182576a5a
Subject(s) - activated clotting time , medicine , aprotinin , partial thromboplastin time , heparin , prothrombin time , clotting time , anesthesia , thrombin time , fibrinogen , serine protease , surgery , coagulation , protease , biochemistry , chemistry , enzyme
The activated clotting time (ACT) is widely used for monitoring heparin anticoagulation during cardiac surgery. Celite-based ACT values are prolonged when aprotinin is administered. MDCO-2010, a novel serine protease inhibitor, is currently being evaluated as a possible alternative to aprotinin. Therefore, we evaluated the in vitro effects of this novel agent on ACT values using 3 different point-of-care instruments with kaolin or celite as an activator.